pharmaceutical

Valeant Pharmaceuticals Announced Q2 Earnings, Shares Jumped

Valeant Pharmaceuticals Announced Q2 Earnings, Shares Jumped

On Tuesday, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) announced its financial results for the second quarter. With earnings beating estimates, shares of the company increased 7.6% to $16.54 per share in morning trading on Tuesday after the announ..

William Ackman to Take Stake in ADP

William Ackman to Take Stake in ADP

On Friday, billionaire investor William Ackman announced that he will be buying a large stake in Automatic Data Processing Inc.(NASDAQ:ADP),  a move that made the U.S. payroll company’s stock increase 16.5% to $120.In recent years, activi..

AstraZeneca Shares fell on Disappointing Q2 Results and Cancer Study Results

AstraZeneca Shares fell on Disappointing Q2 Results and Cancer Study Results

AstraZeneca plc (NYSE: AZN) released a bevy of news today, including Q2 results, as well as study results for two drugs. AZN price has plummeted 15%.Following the loss of exclusivity for Crestor and Seroquel XR AstraZeneca had expected losses in the..

The FDA Scheduled to Review Novartis’ Gene Therapy Drug on Wednesday

The FDA Scheduled to Review Novartis’ Gene Therapy Drug on Wednesday

Novartis AG (NYSE: NVS) is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The U.S. Food and Drug Administration will ask a panel of advisers to focus on the safety of ..

Cara Therapeutic Shares Plummet

Cara Therapeutic Shares Plummet

Shares of Cara Therapeutic Inc. (NASDAQ: CARA) fell 31 percent on Friday after the company announced disappointing results on the CR845 oral medication from a phase 2b trial.Cara is a biopharmaceutical company that focuses on developing medications ..

Clovis Oncology Inc. (NASDAQ: CLVS)Shares Spiked After Positive Phase 3 Data

Clovis Oncology Inc. (NASDAQ: CLVS)Shares Spiked After Positive Phase 3 Data

Clovis Oncology Inc. (NASDAQ: CLVS) is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. The company’s shares jumped ab..

FDA Approves Adamis Pharmaceuticals' EpiPen Competitor

FDA Approves Adamis Pharmaceuticals' EpiPen Competitor

Adamis Pharmaceuticals Corp. (NASDAQ: ADMP) shares jumped more than 60% on Thursday, after the U.S Food and Drug Administration (FDA) approved the Adamis’ Epinephrine injection, a generic version of a Mylan N.V.’s EpiPen, which is a..